305 related articles for article (PubMed ID: 37108955)
1. Diagnosis and Treatment of Invasive Aspergillosis Caused by Non-
Stemler J; Többen C; Lass-Flörl C; Steinmann J; Ackermann K; Rath PM; Simon M; Cornely OA; Koehler P
J Fungi (Basel); 2023 Apr; 9(4):. PubMed ID: 37108955
[TBL] [Abstract][Full Text] [Related]
2. Epidemiology, Drug Susceptibility, and Clinical Risk Factors in Patients With Invasive Aspergillosis.
Wang Y; Zhang L; Zhou L; Zhang M; Xu Y
Front Public Health; 2022; 10():835092. PubMed ID: 35493371
[TBL] [Abstract][Full Text] [Related]
3. Screening for triazole resistance in clinically significant Aspergillus species; report from Pakistan.
Moin S; Farooqi J; Jabeen K; Laiq S; Zafar A
Antimicrob Resist Infect Control; 2020 May; 9(1):62. PubMed ID: 32393344
[TBL] [Abstract][Full Text] [Related]
4. Invasive Aspergillosis by
Rudramurthy SM; Paul RA; Chakrabarti A; Mouton JW; Meis JF
J Fungi (Basel); 2019 Jul; 5(3):. PubMed ID: 31266196
[No Abstract] [Full Text] [Related]
5. Epidemiology and outcome of infections due to Aspergillus terreus: 10-year single centre experience.
Lass-Flörl C; Griff K; Mayr A; Petzer A; Gastl G; Bonatti H; Freund M; Kropshofer G; Dierich MP; Nachbaur D
Br J Haematol; 2005 Oct; 131(2):201-7. PubMed ID: 16197450
[TBL] [Abstract][Full Text] [Related]
6. Aspergillus terreus: an emerging amphotericin B-resistant opportunistic mold in patients with hematologic malignancies.
Hachem RY; Kontoyiannis DP; Boktour MR; Afif C; Cooksley C; Bodey GP; Chatzinikolaou I; Perego C; Kantarjian HM; Raad II
Cancer; 2004 Oct; 101(7):1594-600. PubMed ID: 15378491
[TBL] [Abstract][Full Text] [Related]
7. Increased frequency of non-fumigatus Aspergillus species in amphotericin B- or triazole-pre-exposed cancer patients with positive cultures for aspergilli.
Lionakis MS; Lewis RE; Torres HA; Albert ND; Raad II; Kontoyiannis DP
Diagn Microbiol Infect Dis; 2005 May; 52(1):15-20. PubMed ID: 15878437
[TBL] [Abstract][Full Text] [Related]
8. Prospective survey of Aspergillus species isolated from clinical specimens and their antifungal susceptibility: A five-year single-center study in Japan.
Toyotome T; Saito S; Koshizaki Y; Komatsu R; Matsuzawa T; Yaguchi T
J Infect Chemother; 2020 Feb; 26(2):321-323. PubMed ID: 31564504
[TBL] [Abstract][Full Text] [Related]
9. Patterns of susceptibility of Aspergillus isolates recovered from patients enrolled in the Transplant-Associated Infection Surveillance Network.
Baddley JW; Marr KA; Andes DR; Walsh TJ; Kauffman CA; Kontoyiannis DP; Ito JI; Balajee SA; Pappas PG; Moser SA
J Clin Microbiol; 2009 Oct; 47(10):3271-5. PubMed ID: 19692558
[TBL] [Abstract][Full Text] [Related]
10. In vitro activities of amphotericin B and AmBisome against Aspergillus isolates recovered from Italian patients treated for haematological malignancies.
Colozza C; Posteraro B; Santilli S; De Carolis E; Sanguinetti M; Girmenia C
Int J Antimicrob Agents; 2012 May; 39(5):440-3. PubMed ID: 22429723
[TBL] [Abstract][Full Text] [Related]
11. Trends in the Prevalence of Amphotericin B-Resistance (AmBR) among Clinical Isolates of Aspergillus Species.
Fakhim H; Badali H; Dannaoui E; Nasirian M; Jahangiri F; Raei M; Vaseghi N; Ahmadikia K; Vaezi A
J Mycol Med; 2022 Nov; 32(4):101310. PubMed ID: 35907396
[TBL] [Abstract][Full Text] [Related]
12. In vitro susceptibilities of Aspergillus spp. causing otomycosis to amphotericin B, voriconazole and itraconazole.
Kaya AD; Kiraz N
Mycoses; 2007 Nov; 50(6):447-50. PubMed ID: 17944704
[TBL] [Abstract][Full Text] [Related]
13. Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance Program, 2000.
Pfaller MA; Messer SA; Hollis RJ; Jones RN;
Antimicrob Agents Chemother; 2002 Apr; 46(4):1032-7. PubMed ID: 11897586
[TBL] [Abstract][Full Text] [Related]
14. Molecular identification, phylogenetic analysis and antifungal susceptibility patterns of Aspergillusnidulans complex and Aspergillusterreus complex isolated from clinical specimens.
Mohamadnia A; Salehi Z; Namvar Z; Tabarsi P; Pourabdollah-Toutkaboni M; Rezaie S; Marjani M; Moniri A; Abtahian Z; Mahdaviani SA; Mortezaee V; Askari E; Sharifynia S
J Mycol Med; 2020 Sep; 30(3):101004. PubMed ID: 32534826
[TBL] [Abstract][Full Text] [Related]
15. Susceptibility of fungi isolated from the respiratory tract of falcons to amphotericin B, itraconazole and voriconazole.
Silvanose CD; Bailey TA; Di Somma A
Vet Rec; 2006 Aug; 159(9):282-4. PubMed ID: 16946311
[TBL] [Abstract][Full Text] [Related]
16. The Elevated Endogenous Reactive Oxygen Species Contribute to the Sensitivity of the Amphotericin B-Resistant Isolate of
Liang T; Chen W; Yang X; Wang Q; Wan Z; Li R; Liu W
Front Microbiol; 2021; 12():680749. PubMed ID: 34413836
[No Abstract] [Full Text] [Related]
17. Susceptibility of environmental versus clinical strains of pathogenic Aspergillus.
Araujo R; Pina-Vaz C; Rodrigues AG
Int J Antimicrob Agents; 2007 Jan; 29(1):108-11. PubMed ID: 17189101
[TBL] [Abstract][Full Text] [Related]
18. [Guideline based treatment of invasive aspergillosis].
Karthaus M
Mycoses; 2010 May; 53 Suppl 1():36-43. PubMed ID: 20433655
[TBL] [Abstract][Full Text] [Related]
19. Exogenous Stimulation of Type I Interferon Protects Mice with Chronic Granulomatous Disease from Aspergillosis through Early Recruitment of Host-Protective Neutrophils into the Lung.
Seyedmousavi S; Davis MJ; Sugui JA; Pinkhasov T; Moyer S; Salazar AM; Chang YC; Kwon-Chung KJ
mBio; 2018 Mar; 9(2):. PubMed ID: 29588403
[TBL] [Abstract][Full Text] [Related]
20. A comparative study of the in vitro susceptibilities of clinical and laboratory-selected resistant isolates of Aspergillus spp. to amphotericin B, itraconazole, voriconazole and posaconazole (SCH 56592).
Manavathu EK; Cutright JL; Loebenberg D; Chandrasekar PH
J Antimicrob Chemother; 2000 Aug; 46(2):229-34. PubMed ID: 10933645
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
